This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The in vivo administration of monoclonal antibodies that bind to cell-surface molecules can block the actions mediated by those molecules, deliver stimulatory signals through the bound molecules, or result in depletion of the targeted cell population. This approach has been extremely useful to study immunopathogenic events in rodent models. To enhance the usefulness of existing nonhuman primate models of disease, we have developed new fully human monoclonal antibodies for in vivo administration to macaque monkeys. These new antibodies were developed by cloning and expressing M. mulatta CD40 and IL-10 proteins. Resulting hybridomas from humanized mice immunized with these recombinant, nonhuman primate proteins were screened for reactivity with PBMC and native proteins from rhesus monkeys. We also performed in vivo evaluation of monoclonal antibodies targeting B cells and natural killer (NK) cells. The ability of these candidate research reagents to deplete the targeted lymphocyte subpopulation was assessed.
Showing the most recent 10 out of 365 publications
